Engineering multiple U7snRNA constructs to induce single and multiexon-skipping for Duchenne muscular dystrophy.

Engineering multiple U7snRNA constructs to induce single and multiexon-skipping for Duchenne muscular dystrophy.

Taispeáin leaganacha eile (1)

Duchenne muscular dystrophy (DMD) is a fatal muscle wasting disorder caused by mutations in the dystrophin gene. Antisense-mediated exon skipping is one of the most promising approaches for the treatment of DMD but still faces personalized medicine challenges as different mutations found in DMD pati...

Cur síos iomlán

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí:	Goyenvalle, A, Wright, J, Babbs, A, Wilkins, V, Garcia, L, Davies, K
Formáid:	Journal article
Teanga:	English
Foilsithe / Cruthaithe:	2012

Míreanna comhchosúla

Engineering multiple U7snRNA constructs to induce single and multiexon-skipping for Duchenne muscular dystrophy
de réir: Goyenvalle, A, et al.
Foilsithe / Cruthaithe: (2012)

AAV-U7snRNA mediated multi exon-skipping for Duchenne muscular dystrophy
de réir: Goyenvalle, A, et al.
Foilsithe / Cruthaithe: (2011)

AAV-U7snRNA mediated multi exon-skipping for Duchenne muscular dystrophy
de réir: Goyenvalle, A, et al.
Foilsithe / Cruthaithe: (2010)

Engineering exon-skipping vectors expressing U7 snRNA constructs for Duchenne muscular dystrophy gene therapy.
de réir: Goyenvalle, A, et al.
Foilsithe / Cruthaithe: (2011)

Assessment of the feasibility of exon 45–55 multiexon skipping for duchenne muscular dystrophy
de réir: van Ommen Gert-Jan B, et al.
Foilsithe / Cruthaithe: (2008-12-01)

Upgrading U7snRNA To Complete Efficient Rescue of Dystrophin by Exon-Skipping in DMD Patients
de réir: Goyenvalle, A, et al.
Foilsithe / Cruthaithe: (2009)

Rescue of severely affected dystrophin/utrophin-deficient mice through scAAV-U7snRNA-mediated exon skipping
de réir: Goyenvalle, A, et al.
Foilsithe / Cruthaithe: (2012)

Rescue of severely affected dystrophin/utrophin-deficient mice through scAAV-U7snRNA-mediated exon skipping.
de réir: Goyenvalle, A, et al.
Foilsithe / Cruthaithe: (2012)

Enhanced exon-skipping induced by U7 snRNA carrying a splicing silencer sequence: Promising tool for DMD therapy.
de réir: Goyenvalle, A, et al.
Foilsithe / Cruthaithe: (2009)

The Cellular Processing Capacity Limits the Amounts of Chimeric U7 snRNA Available for Antisense Delivery.
de réir: Eckenfelder, A, et al.
Foilsithe / Cruthaithe: (2012)

The Cellular Processing Capacity Limits the Amounts of Chimeric U7 snRNA Available for Antisense Delivery
de réir: Agathe Eckenfelder, et al.
Foilsithe / Cruthaithe: (2012-01-01)

Challenges to oligonucleotides-based therapeutics for Duchenne muscular dystrophy.
de réir: Goyenvalle, A, et al.
Foilsithe / Cruthaithe: (2011)

AAV genome loss from dystrophic mouse muscles during AAV-U7 snRNA-mediated exon-skipping therapy
de réir: Le Hir, M, et al.
Foilsithe / Cruthaithe: (2013)

Challenges to oligonucleotides-based therapeutics for Duchenne muscular dystrophy
de réir: Goyenvalle Aurélie, et al.
Foilsithe / Cruthaithe: (2011-02-01)

Long-Term Efficacy of AAV9-U7snRNA-Mediated Exon 51 Skipping in mdx52 Mice
de réir: Philippine Aupy, et al.
Foilsithe / Cruthaithe: (2020-06-01)

Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy
de réir: van Ommen Gert-Jan B, et al.
Foilsithe / Cruthaithe: (2007-07-01)

From diagnosis to therapy in Duchenne muscular dystrophy
de réir: Babbs, A, et al.
Foilsithe / Cruthaithe: (2020)

The potential of utrophin and dystrophin combination therapies for Duchenne muscular dystrophy
de réir: Guiraud, S, et al.
Foilsithe / Cruthaithe: (2019)

New Approach for Antisense Oligonucleotide-Mediated Exon Skipping in Duchenne Muscular Dystrophy.
de réir: Aoki, Y, et al.
Foilsithe / Cruthaithe: (2012)

Targeting Duchenne muscular dystrophy by skipping DMD exon 45 with base editors
de réir: Michael Gapinske, et al.
Foilsithe / Cruthaithe: (2023-09-01)

Exon skipping for Duchenne muscular dystrophy: a systematic review and meta-analysis
de réir: Yuko Shimizu-Motohashi, et al.
Foilsithe / Cruthaithe: (2018-06-01)

Rescue of cardiomyopathy through U7snRNA‐mediated exon skipping in Mybpc3‐targeted knock‐in mice
de réir: Christina Gedicke‐Hornung, et al.
Foilsithe / Cruthaithe: (2013-05-01)

Possibility of exon skipping therapy for Duchenne muscular dystrophy in Russian patients: present and future
de réir: E. V. Zinina, et al.
Foilsithe / Cruthaithe: (2024-09-01)

Progress in therapy for Duchenne muscular dystrophy.
de réir: Fairclough, R, et al.
Foilsithe / Cruthaithe: (2011)

Progress in therapy for Duchenne muscular dystrophy
de réir: Fairclough, R, et al.
Foilsithe / Cruthaithe: (2011)

Utrophin in the therapy of Duchenne Muscular Dystrophy
de réir: Potter, A, et al.
Foilsithe / Cruthaithe: (2006)

Exon skipping peptide-pmos for correction of dystrophin in mouse models of duchenne muscular dystrophy
de réir: Betts, C, et al.
Foilsithe / Cruthaithe: (2014)

Regenerative biomarkers for Duchenne muscular dystrophy
de réir: Guiraud, S, et al.
Foilsithe / Cruthaithe: (2019)

Duchenne Muscular Dystrophy
de réir: J Gordon Millichap
Foilsithe / Cruthaithe: (1989-05-01)

Regenerative biomarkers for Duchenne muscular dystrophy
de réir: Simon Guiraud, et al.
Foilsithe / Cruthaithe: (2019-01-01)

Therapeutic approaches for Duchenne muscular dystrophy
de réir: Roberts, TC, et al.
Foilsithe / Cruthaithe: (2023)

Duchenne muscular dystrophy: recent insights in brain related comorbidities
de réir: Cyrille Vaillend, et al.
Foilsithe / Cruthaithe: (2025-02-01)

Utrophin upregulation in Duchenne muscular dystrophy.
de réir: Hirst, R, et al.
Foilsithe / Cruthaithe: (2005)

Challenges for antisense oligonucleotide-based therapeutics, in particular for exon 51-skipping in Duchenne muscular dystrophy
de réir: Aoki, Y, et al.
Foilsithe / Cruthaithe: (2011)

CRISPR-Cas9-mediated exon skipping as a cardioprotective strategy in Duchenne muscular dystrophy
de réir: Harry Wilton-Clark, et al.
Foilsithe / Cruthaithe: (2023-09-01)

Newborn screening of duchenne muscular dystrophy specifically targeting deletions amenable to exon-skipping therapy
de réir: Pablo Beckers, et al.
Foilsithe / Cruthaithe: (2021-02-01)

Upper limb disease evolution in exon 53 skipping eligible patients with Duchenne muscular dystrophy
de réir: Charlotte Lilien, et al.
Foilsithe / Cruthaithe: (2021-10-01)

Evaluation of 2’-Deoxy-2’-fluoro Antisense Oligonucleotides for Exon Skipping in Duchenne Muscular Dystrophy
de réir: Silvana M G Jirka, et al.
Foilsithe / Cruthaithe: (2015-01-01)

Duchenne muscular dystrophy - past, present and future
de réir: Davies, K
Foilsithe / Cruthaithe: (2002)

Pharmacological advances for treatment in Duchenne muscular dystrophy
de réir: Guiraud, S, et al.
Foilsithe / Cruthaithe: (2017)